# ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer

> **NCT01963052** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 93 (actual)

## Conditions studied

- Metastatic Urothelial Cancer

## Interventions

- **DRUG:** AGS15E

## Key facts

- **NCT ID:** NCT01963052
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11-14
- **Primary completion:** 2019-07-08
- **Final completion:** 2019-07-08
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2024-11-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01963052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01963052, "ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT01963052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*